MedPath

Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography

Not yet recruiting
Conditions
Coronary Artery Disease
Coronary Atheroscleroses
Interventions
Diagnostic Test: CT coronary angiography and non-contrast CT
Registration Number
NCT06438393
Lead Sponsor
Universidade do Porto
Brief Summary

This project aims to improve direct patient care by reducing the risks of futile exposure to ionizing radiation and iodinated contrast in patients referred for coronary computed tomography angiography

Detailed Description

Since the last NICE guidelines update recommending computed tomography coronary angiography (CTCA) as the first line of investigation for patients with suspected coronary artery disease (CAD), there has been a high burden in the healthcare system and unnecessary exposition to radiation and iodine-containing contrast medium, especially in the youngest. Around 35% of patients who currently undergo CTCA have normal coronaries which means those patients were unnecessary exposed to radiation and contrast. A CTCA screening strategy to rule out CAD is needed to comply with the ALARA ("As Low As Reasonable Achievable") principles preventing radiation risks, reducing unnecessary scans and directing healthcare resources to those who will benefit from a CTCA.

We designed the SAFE-CT (Screening coronary Artery disease using artiFicial intelligencE in noncontrast Computed Tomography) study to develop a state-of-art artificial intelligence method to detect CAD as defined on CTCA using high-dimensional data (radiomics) extracted from the non-contrast cardiac computed tomography (CT). The model will be trained in 15,000 subjects scanned with paired non-contrast CT and CTCA and externally validated in an independent cohort of 1,000 subjects. In a preliminary analysis, non-contrast CT radiomics improved calcium score performance and discriminated CAD with an AUC of 0.91 (95% CI: 0.83-1.00). The algorithm will be converted into a user-friendly plugin to automatically decide whether the patient needs contrast. A real-world multicentre cohort study will be planned for software prospective validation and the creation of a large-scale proteomic biobank to support the translation of imaging biomarkers worldwide.

SAFE-CT can change the current CT scanning workflow by creating software that accurately rules out any CAD in \>1/3 of patients referred for CTCA with low radiation and no contrast. This accurate machine learning model will be optimized to reach \>90% sensitivity and negative predictive value and will bring several advantages for patients and the healthcare system:

* Prevention of radiation and contrast exposition.

* Increased CTCA scanning capacity for complex cases.

* Widespread use of CT for CAD exclusion in the emergency department and in outpatient clinics of centres with no CTCA.

* Improved screening tool for CAD in asymptomatic subjects.

* Up- and downstream cost reduction.

The SAFE-CT project proposes a safer, low-cost, and personalized CTCA scanning strategy that fosters scientific and technological innovation with the potential to bring improvement to patient care and clinical practice, and, thereby, societal, and economic impact.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Patient with stable chest pain who underwent a CTCA
Exclusion Criteria
  • Missing non-contrast CT image (coronary calcium score image)
  • Known coronary artery disease
  • Prior myocardial infarction
  • Prior PCI or CABG

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Stable chest pain and unknown CAD who underwent CTCA and CCS in the same scanning sessionCT coronary angiography and non-contrast CTCAD: Presence of minimal coronary artery disease (i.e., coronary stenosis 0-25%) Normal coronary arteries: No visible coronary atherosclerosis
Primary Outcome Measures
NameTimeMethod
Implement a machine learning model to discriminate patients with no CAD from patients with at least minimal disease (CAD-RADS=0 vs. CAD-RADS>0).3 years
Create a national registry of cardiac CT3 years
Build a non-contrast CT radiomic signature of CAD3 years
Build a user-friendly plugin to facilitate users experience and distribution of our technology in clinical practice.3 years
Implement a machine learning model to detect coronary inflammation as defined using the Fat Attenuation Index (FAI ≥ -70.1 HU) in patients with no visible coronary plaque (CAD-RADS=0).3 years
Evaluate the real-world operationality and performance of the plugin in an international multicentre prospective cohort study.3 years
Secondary Outcome Measures
NameTimeMethod
Setup a public CT imaging repository3 years
Setup a human blood biobank to identify the peripheral blood mononuclear cells (PBMCs) and plasma proteomics associated with CT data and clinical outcomes.3 years

Trial Locations

Locations (1)

Faculty of Medicine of Porto

🇵🇹

Porto, Portugal

© Copyright 2025. All Rights Reserved by MedPath